Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2021-10-25 Earnings Release
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Imfinzi improved survival in biliary tract cancer
Earnings Release Classification · 99% confidence The document begins with 'RNS Number : 1081Q' and is dated '25 October 2021'. It contains a headline announcing clinical trial results ('Imfinzi plus chemotherapy significantly improved overall survival in 1st-line advanced biliary tract cancer in TOPAZ-1 Phase III trial'). The content is a press release detailing scientific and clinical updates, not a formal financial report (like 10-K or IR) or a short announcement of a report. The presence of the RNS identifier and the nature of the announcement (drug trial results) strongly suggest it is a general regulatory announcement disseminated via the RNS system. Since there is no specific category for clinical trial results, the most appropriate fallback is 'Regulatory Filings' (RNS), as it is explicitly distributed through the RNS service. Q4 2021
2021-10-25 English
AZ RECOMMENDS ADS HOLDERS REJECT MINI-TENDER OFFER
Foreign Filer Report
2021-10-18 English
AZ recommends ADS holders reject mini-tender offer
Legal Proceedings Report Classification · 99% confidence The document is identified by the RNS Number header and the explicit mention that the information is provided by RNS, the news service of the London Stock Exchange. The content is an announcement regarding an unsolicited 'mini-tender' offer by a third party (TRC Capital) and AstraZeneca's recommendation for shareholders to reject it. This type of market-sensitive, non-periodic disclosure that doesn't fit into specific financial reporting categories (like 10-K, ER, or IR) is best classified as a general regulatory announcement or filing. Since it is a direct communication to the market via the RNS system, the most appropriate classification is Regulatory Filings (RNS), which serves as the general regulatory announcement fallback.
2021-10-18 English
IMFINZI & TREMELIMUMAB IMPROVED OS IN LIVER CANCER
Foreign Filer Report
2021-10-15 English
Imfinzi & tremelimumab improved OS in liver cancer
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number : 2136P' and is dated '15 October 2021'. It contains a headline announcing clinical trial results ('Imfinzi plus tremelimumab significantly improved overall survival in HIMALAYA Phase III trial in 1st-line unresectable liver cancer'). The content details scientific findings, quotes from R&D executives, and notes about the trial design. Crucially, it ends with boilerplate text referencing 'RNS, the news service of the London Stock Exchange' and 'This information is provided by RNS'. This structure strongly indicates a regulatory news service announcement, which is typically classified as a general Regulatory Filing (RNS) or, more specifically, an Earnings Release (ER) if it pertains to financial results. Since this is a clinical trial update (a significant corporate event but not a standard quarterly financial report), and it is explicitly distributed via RNS, the most appropriate classification is RNS, as it is a general regulatory announcement distributed through that channel, or potentially ER if the context implies it's the primary release of period-related data, but RNS is safer for non-standard regulatory news.
2021-10-15 English
AZD7442 PHIII TRIAL POSITIVE IN COVID OUTPATIENTS
Foreign Filer Report
2021-10-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.